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Background: Elevated expression of focal adhesion kinase (FAK) occurs in numerous human cancers including colon-,
cervix- and breast cancer. Although several studies have implicated FAK in mammary tumour formation induced by
ectopic oncogene expression, evidence supporting a role for FAK in spontaneous mammary tumour development
caused by loss of tumour suppressor genes such as p53 is lacking. Alterations in the tumour suppressor gene p53 have
been implicated in over 50% of human breast cancers. Given that elevated FAK expression highly correlates with p53 mutation
status in human breast cancer, we set out to investigate the importance of FAK in p53-mediated spontaneous mammary tumour
development.
Methods: To directly assess the role of FAK, we generated mice with conditional inactivation of FAK and p53.
We generated female p53lox/lox/FAKþ /þ /WapCre, p53lox/lox/FAKflox/þ /WapCre and p53lox/lox/FAKflox/ /WapCre mice,
and mice with WapCre-mediated conditional expression of p53R270H, the mouse equivalent of human p53R273H hot
spot mutation, together with conditional deletion of FAK, P53R270H/þ /FAKlox/þ /WapCre and p53R270H/þ /FAKflox/ /WapCre
mice. All mice were subjected to one pregnancy to induce WapCre-mediated deletion of p53 or expression of
p53 R270H, and Fak genes flanked by two loxP sites, and subsequently followed the development of mammary
tumours.
Results: Using this approach, we show that FAK is important for p53-induced mammary tumour development. In addition, mice
with the mammary gland-specific conditional expression of p53 point mutation R270H, the mouse equivalent to human R273H,
in combination with conditional deletion of Fak showed reduced incidence of p53R270H-induced mammary tumours. In both
models these effects of FAK were related to reduced proliferation in preneoplastic lesions in the mammary gland ductal
structures.
Conclusions: Mammary gland-specific ablation of FAK hampers p53-regulated spontaneous mammary tumour formation. Focal
adhesion kinase deletion reduced proliferative capacity of p53 null and p53R270H mammary epithelial cells but did not lead to
increased apoptosis in vivo. Our data identify FAK as an important regulator in mammary epithelial cell proliferation in p53-
mediated and p53R270H-induced mammary tumour development.
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The tumour suppressor p53 has been implicated in diverse
biological processes such as apoptosis, cell-cycle arrest, DNA
repair, cellular differentiation and senescence, and has been shown
to be altered in over 50% of spontaneous tumours in humans
(Cance et al, 2000; Wijnhoven et al, 2005; Dey et al, 2008). In
addition to spontaneous tumours, germ-line mutations in p53 are
observed in Li-Fraumeni patients, which predisposes them to a
wide spectrum of early-onset cancers, including breast cancers
(Malkin et al, 1990; Srivastava et al, 1990; Hainaut and Hollstein,
2000). Normally, p53 is expressed in a latent form and is
maintained at low levels through targeted degradation. However,
in response to DNA damage or stress, p53 is activated to function
as a transcription factor, resulting in a cascade of events that
eventually prevents tumour development. P53 is the most
frequently mutated gene in spontaneous breast tumours. Approxi-
mately 30% of sporadic breast tumours acquire p53 mutations,
which are related to breast cancer progression and resistance to
doxorubicin therapy in breast cancer patients (Hainaut and
Hollstein, 2000; Wijnhoven et al, 2005; Dey et al, 2008).
Focal adhesion kinase (FAK), a non-receptor protein tyrosine
kinase, specifically associates with cell-matrix adhesions where it
integrates signals from integrins and growth factor receptors to
coordinate and control processes such as actin cytoskeleton
dynamics and migration. Focal adhesion kinase expression is
elevated in numerous cancers including colon-, cervix- and breast
cancer (Cance et al, 2000; Moon et al, 2003; Lightfoot et al, 2004;
Madan et al, 2006; Pylayeva et al, 2009), and FAK overexpression
and p53 mutations correlate with human breast cancer (Lightfoot
et al, 2004). To study the role of FAK, FAK gene knockout mice
were developed but led to an embryonic lethal phenotype at day
E8.5 due to defects in the axial mesodermal tissues and
cardiovascular system (Ilic et al, 1995, 2003). Using conditional
mouse models, the importance of FAK in skin tumour progression
was shown (McLean et al, 2001), and several studies were
performed to determine the role of FAK in mammary gland
tumour development and progression (Lahlou et al, 2007, 2012;
Provenzano et al, 2008; Luo et al, 2009; Pylayeva et al, 2009). Focal
adhesion kinase deletion in MMTV-PyMT and activated ErbB2
(NDL2-5) models reduced the incidence of mammary tumours,
suggesting an important role for FAK in mammary gland tumour
development. PyMT is a strong proto-oncogene inducing the onset
of mammary gland tumours within 10 weeks, and also ErbB2-
induced mammary tumours developed early, around 20 weeks
(Lahlou et al, 2012). This precludes the analysis of the role of FAK
in spontaneous mammary gland tumour development as a
consequence of loss of heterozygosity of tumour suppressors,
which is more relevant to the human situation. Consequently, these
studies were unable to address the role of FAK in the natural
course of mammary tumorigenesis (Lahlou et al, 2007; Provenzano
et al, 2008; Luo et al, 2009; Pylayeva et al, 2009). p53 has been
shown to affect FAK levels by binding to the N-terminal region of
FAK as well as to the promoter region of FAK to inhibit the
transcription of FAK (Golubovskaya et al, 2008). Vice versa, FAK
facilitates p53 turnover via enhanced MDM2-dependent p53
ubiquitination, and subsequent proteosomal degradation leading
to inactivation of p53 (Lim et al, 2008). This mutual interaction
suggests interplay in cancer development, which so far has not
been investigated.
To study the role of FAK in spontaneous mammary gland
tumour development, here, we used two independent spontaneous
mammary tumorigenesis models that are dependent on the tumour
suppressor protein p53. The first model was based on conditional
deletion of the p53, resulting in induction of mammary tumours
after 45 weeks. In the second model, we explored the contribution
of FAK to mammary gland tumour development induced by a p53
point mutation p53R270H, the mouse equivalent of human p53R273H
mutation. Such p53 point mutation leads to dominant-negative
inhibition of wild-type p53 function, and expression of mammary
gland-specific p53R270H mutation has been shown to mimic human
breast cancer development (De Vries et al, 2002). Both mouse
models were crossed with conditional FAKflox/ mice and WapCre
mice. Expression of the WapCre transgene is restricted to the
mammary glands of late pregnant and lactating mice, and is not
expressed in virgin mice (Wagner et al, 1997). Mice were subjected
to one pregnancy to allow mammary-specific inactivation of both
p53 and FAK. Using these two independent spontaneous
mammary tumorigenesis models, we show that FAK is essential
for the progression of mammary epithelial hyperplasia to
mammary gland tumours caused by either loss of p53 or
expression of the p53R270H mutant through inhibition of cell
proliferation in preneoplastic lesions.
MATERIALS AND METHODS
Genotyping of mice. Genotyping of p53lox/lox mice was performed
using the following primers. 50-CAC AAA AAC AGG TTA AAC
CCA G-30 [p53-int1-fwd], 50-AGC ACA TAG GAG GCA GAG
AC-30 [p53-int1-rev], 50-AAG GGG TAT GAG GGA CAA GG-30
[p53-int10-fwd], 50GAA GAC AGA AAA GGG GAG GG-30
[p53-int10-rev]. Deletion of p53 was confirmed with primers:
50-CAC AAA AAC AGG TTA AAC CCA G-30 [p53-int1-fwd] and
50GAA GAC AGA AAA GGG GAG GG-30 [p53-int10-rev].
Genotyping of p53LSLR270H was performed using a PCR/
digestion-based assay as described previously (Wijnhoven et al,
2005). Genotyping of fak was performed using specific primers for
FAK: 50-GAGAATCCAGCTTTGGCTGTT-30; 50-GGCTTCTTGA
AGGAACTTCTC-30; 50-TGATATTGCTGAAGAGCTTGGCG G-30.
PCR products derived were FAK wt 88 and/or FAK mutant 170 bp;
for FAKflox mice the primers are fwd: 50-GAGAATCCAGC
TTTGGCTGTTG-30, rev: 50-GAATGCTACAGGAACC AAA
TAAC-30, PCR products were Wt 290 bp and lox 400 bp. For
Cre-genotyping primers used were fwd: 50-GTTCAGGGATCGC
CAGGC G-30 and rev: 50-GCTGGCTGGTGGCAGATGG-30. Focal
adhesion kinase recombination was determined using the following
primers fwd: 50-GACCTTCAACTTCTCATTTCTCC-30 and rev:
50-GAATGCTACAGGAACCAAATAAC-30; PCR products were
Wt 1.4 kB, lox 1.6 kB and FAK-recombined allele 327 bp. All mice
were on a mixed C57jBl6/Ola background.
Analysis of spontaneous tumour development. Spontaneous
tumour development was determined in p53lox/lox/FAKþ /þ
(n¼ 25), p53lox/lox/FAKflox/ (n¼ 25) and p53lox/lox/FAKflox/þ
(n¼ 25), and in p53R270H/FAKflox/þ /WapCre (n¼ 13) and
p53R270H/FAKflox/ /WapCre mice (n¼ 20). At the age of 8 weeks,
mice were placed in breeding; pregnancy and lactation stimulated
the WapCre promoter. After 3 weeks of weaning, the pups were
taken away from the mother. Weight development and mammary
tumour formation were monitored once a week. Mammary tumour
formation was followed on a weekly basis by palpation up to 70
weeks for p53R270H mammary tumour development and up to 90
weeks for p53lox/lox mammary tumour development. Mice were
killed before tumours reached the size of 1 cm3 or when mice lost
more than 10% of their total body weight.
All animal experiments were approved by the local ethical
committee. Housing and experiments were performed according to
the Dutch guidelines for the care and use of laboratory animals (UL-
DEC-05099). Sterilised food and water were provided ad libitum.
Tissue processing and histology. Tumours and/or mammary
glands isolated from the mice were fixed in 4% formaldehyde and
subsequently processed and embedded in paraffin or snap-frozen in
liquid nitrogen. Paraffin sections of 3mm were de-paraffinised, and
antigen retrieval was performed when needed. Sections were stained
with the primary antibody overnight at 4oC and with the secondary
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antibody for 1 h at room temperature. Slides were mounted with
aqua polymount (Polysciences, Eppelheim, Germany).
Immunofluorescence microscopy and image analysis. Immuno-
fluorescence staining was performed as described previously (De
Graauw et al, 2005). Primary antibody incubation was performed
overnight at 4 1C, and tumours were subsequently incubated with
the Alexa-488 or Cy-3-conjugated secondary antibody (Molecular
Probes, Bleiswijk, The Netherlands). Microscopic analysis was
performed using a Bio-Rad Radiance 2100 confocal system with a
 60 or  40 Plan Apo (NA 1.4; Nikon) objective lens. Image
acquisition was controlled using the Laser Sharp software
(Bio-Rad, Hercules, CA, USA). Images were processed, and
quantitative image analysis was performed using Image-Pro Plus
(Version 5.1; Media Cybernetics, Rockville, MD, USA).
Western blot analysis. A small biopsy from the tumours was lysed
using lysis buffer (Tris-HCl (10mM), sucrose (250mM), EDTA
(1mM). Western blotting was performed as previously described
(De Graauw et al, 2005). Primary antibody incubation was
performed overnight at 4 1C. Thereafter, blots were incubated
with horseradish peroxidase-conjugated secondary antibody (GE
Healthcare, Fairfield, CT, USA) or Cy5-conjugated secondary
antibody in Tris-buffered saline-Tween 20 for 1 h at room
temperature. Protein signals were detected with the ECL-plus
method (GE Healthcare) followed by scanning of the blots, or, in
case of Cy5 incubation, the blots were directly scanned with a
Typhoon 9400 imager (GE Healthcare).
Antibodies. Anti-FAK clone 4.47, Upstate Biotechnology (Lake
Placid, NY, USA) (#05-537); anti-E-cadherin, BD transduction
(San Jose, CA, USA) (#610263); anti-vimentin, Sigma Aldrich
(St Louis, MO, USA) (V-4630); anti-cytokeratin 5, Covance
(Rotterdam, The Netherlands) (#PRB-160P); anti-cytokeratin 8,
Fitzgerald (North Acton, MA, USA) (rdi-pro61038); anti-p53
CM5, Novocastra (Rijswijk, The Netherlands) (p53-CM5P);
anti-p21, Santa Cruz (Dallas, TX, USA) (sc-397); anti-p53Ser15,
Cell Signaling Technology (Danvers, MA, USA) (9284);
anti-Tubulin, Sigma Aldrich (T-9026); b-actin Santa Cruz
(sc-47778), anti-FAK (IHC), Cell Signalling Technology (#3258).
Gene expression analysis. Mouse mammary tumour RNA
was purified using an RNeasy minikit (Qiagen, Venlo,
The Netherlands). The samples were hybridised to Affymetrix
microarrays. We generated mu-sigma normalised log gene
expression values and clustered the mice using Euclidean distance
on average linkage using R version 2.15.2 and the package gplots
version 2.11.0. We focused on selected basal-like genes, including
Trp63, Krt17, Cryab, Ptn, Col17a1 and Slug (snai2). Genes were
not reordered.
We employed principal components and hierarchical cluster
analysis to determine gene expression differences in tumours
derived from FAKþ / and FAK / mice in R version 3.0.1
(R Development Core Team).
We calculated the average expression values over all probes
targeting the same gene, log-transformed and applied gene wise
normalisation, resulting in a data set of 21 449 probes. We used the
top 10 varying genes in these analyses for visualisation. To test
sensitivity to this cut-off, we checked whether results were different
if top5, top25, top50 or all genes were included in the analysis (data
not shown). We used 1-Pearson correlation as distance metric and
Ward’s method for clustering. We used BootstrapClusterTest from
the ClassDiscovery package for determining the robustness of the
presence of two clusters by sampling 2000 genes 200 times
(Coombes, 2009).
To determine significantly differing genes between FAKþ /
and FAK / tumours, we employed a two-class unpaired SAM
analysis (Tibshirani et al, 2011) on log10 gene expression values of
the data set.
Statistics. Survival curves were generated using Kaplan–Meier
statistics. Significance was estimated using unpaired two-tailed
Student’s t-test and Log-rank (Mantel-Cox) test.
RESULTS
Mammary-specific disruption of Fak inhibits spontaneous
mammary gland tumour formation in p53lox/lox mice. Given
the importance of FAK in mammary tumour formation as shown
using two independent strong oncogenes (Lahlou et al, 2007, 2012;
Provenzano et al, 2008; Luo et al, 2009; Pylayeva et al, 2009) and
the potential interplay of FAK and p53 in cancer, we assessed
whether FAK was important in p53-mediated spontaneous
mammary tumour development. We generated female WapCre/
p53lox/lox/FAKþ /þ (FAKþ /þ ), WapCre/p53lox/lox/FAKflox/þ
(FAKflox/þ ) and WapCre/p53lox/lox/FAKflox/ (FAKflox/ ) mice.
The mice were subjected to one pregnancy to induce WapCre-
mediated deletion of p53 and Fak genes flanked by two loxP sites,
and subsequently followed the development of mammary tumours
for a total time period of 90 weeks. The first onset of mammary
tumours in FAKflox/ mice was comparable to that in FAKflox/þ
mice. However, mammary tumour formation reached a plateau in
FAKflox/ mice after 60 weeks, but continued in FAKþ /þ and
FAKflox/þ animals (Figure 1A). This was reflected in the effect on
the total number of mammary tumours that developed: 52%
FAKflox/þ mice developed mammary tumours (13 of a total of 25
mice), while only t36% FAKflox/ mice developed mammary
tumours (9 of a total of 25 mice) (Table 1). FAKflox/þ mice were
similarly susceptible for mammary tumour development compared
with FAKþ /þ ; however, FAKflox/ mice displayed a significant
difference (Figure 1A, unpaired t-test Po0.05). Sixty-four percent
of FAKþ /þ mice were mammary tumour bearing (16 of a total of
25 mice), and mean latency time for spontaneous mammary
tumour development was 62 weeks for FAKþ /þ mice. The mean
latency time for spontaneous mammary tumour development was
67 weeks for FAKflox/þ mice and 60 weeks for FAKflox/ mice.
While contralateral mammary glands from tumour-bearing mice
all displayed hyperplasia regardless of genotype, mammary glands
from early and late dropouts in FAK flox/ mice (censored events)
did not display hyperplasia, indicating that these mice would not
have developed mammary tumours within our experimental
setting. To determine FAK recombination efficiency, mammary
tumours from FAKflox/þ and FAKflox/ mice were analysed by
PCR (Figure 1B). Fak gene recombination was confirmed in
FAKflox/þ and FAKflox/ mammary tumours (Figure 1B).
Together, these data suggest that FAK is important for
p53-mediated mammary tumour development.
On the basis of their histological and structural organisation, the
vast majority of mammary tumours were classified as solid
carcinomas and carcinosarcomas, the latter characterised by the
presence of spindle-shaped cells (Figure 1C, Table 1). Confirma-
tively, carcinosarcomas stained positive for vimentin and negative
for E-cadherin (Supplementary Figure 1). Histological analysis of
mammary glands isolated from the contralateral side of the
mammary tumour revealed neoplastic or hyperplastic lesions in all
groups (Figure 1C, upper panel), indicating that oncogenic
transformation occurred in both FAK-expressing and FAK-deleted
mammary glands.
Focal adhesion kinase-proficient and -deficient mammary
tumours are genetically comparable. To test the effect of FAK
gene recombination on protein level, FAKflox/þ and FAKflox/ and
control mammary tumours (FAKþ /þ ) were analysed for FAK
protein expression. Focal adhesion kinase protein expression
determined by western blot analysis and FAK staining on paraffin
sections were clearly reduced in FAKflox/þ and FAKflox/
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mammary tumours compared with control mammary tumours
(FAKþ /þ ), indicating that ablation of FAK was successful on both
gene and protein level (Figure 2A–C). An interesting observation is
that the few mammary tumours that do arise in FAKflox/ mice
share similar mammary tumour latency as compared with
mammary tumour development in FAKflox/þ mice. As FAK status
was significantly reduced in FAKflox/ mammary tumours, we
wondered whether FAKflox/ tumours use alternative strategies to
facilitate tumour development. To unravel potential alternative
pathways, we performed gene expression analysis on FAKflox/
and FAKflox/þ mammary tumours. Unsupervised hierarchical
clustering and principle component analysis on these tumours
revealed that the FAKflox/ and FAKflox/þ groups do not show
clear separation based on gene expression, suggesting that the
mammary tumours are genetically comparable (Supplementary
Figure 2). This was supported by SAM analysis to determine
significant changes in gene expression between FAKþ / and
FAK / tumours, which revealed only 28 genes that showed
significant higher expression in FAKflox/þ compared with that in
FAKflox/ (Supplementary Table 1). However, we did observe that
hierarchical clustering and principal components analysis identi-
fied mainly separate histological subtype, that is, solid carcinoma vs
carcinosarcoma, but this was not related to FAK status (Odd
ratio¼ 3.6, P¼ 0.34). One outlier sample turned out to be a
lymphoma and was excluded from SAM analysis. When we
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Figure 1. FAK is essential for p53lox/lox-induced mammary
tumorigenesis. Female FAKþ /þ (n¼ 25), FAKflox/þ (n¼25) and
FAKflox/ mice (n¼ 25) were subjected to one pregnancy to induce
WapCre-mediated deletion of p53 and Fak, and subsequently followed
for the development of mammary tumours for a total time period of 90
weeks. (A) Mammary tumour-free survival (%) (Log-rank Po0.05,
unpaired t-test Po0.05) (B) FAK recombination PCR on mammary
tumours. FAK wt is 1.4 kb, FAK lox is 1.6 kb and FAK recombined is
327bp. (C) Paraffin sections of mammary tumours and non-tumour-
bearing mammary glands stained for hematoxylin/eosin (HE).
Table 1. Tumour spectrum in FAKþ /þ , FAKflox/þ and FAKflox/ p53lox/lox
mice
FAKþ /þ FAKflox/þ FAKflox/
Total number of mice
analysed
25 25 25
Tumour-bearing mice 18 14 11
Mammary gland tumoura 16 (64%) 13 (52%) 9 (36%)
Lymphoma 0 0 1
Otherb 2 1 1
Mean mammary gland tumour
latency (weeks)c
61.9±12.3 67.2±11.0 59.7±10.7
aThe majority of mammary gland tumours that developed were characterised as solid
carcinomas and carcinosarcomas.
bOther tumours were found in the lung, bone and colon.
cMean latency time is depicted as the number of weeks after ablation of p53lox/lox.
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Figure 2. Fak gene recombination was successful on both gene and
protein levels. (A) FAK staining on paraffin sections of mammary
tumours. (B) Western blot analysis was performed on lysates of
mammary tumours. Membranes were incubated with antibodies
against FAK. Actin was used as a loading control. (C) Quantification of
the FAK protein level. Results represent the mean of six individual
tumours per genotype (± s.d.), from which a representative western
blot is shown in B.
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sampled 200 times a clustering with 2000 genes (similar to
visualisation, Supplementary Figure 2), we observed that the
clusters were robust, with some samples from FAKflox/þ clustering
with FAKflox/ samples, representing similar tumour types.
Given that FAK-null mammary tumours genetically resemble
FAK-proficient tumours and the sparse mammary tumours that
arise show the same latency, a plausible explanation for this
phenomenon is that, at the time of mammary tumour initiation
and early mammary tumour development, FAK has not been
deleted efficiently, which is supported by some residual cells that
still showed clear FAK expression (Figure 2B).
Mammary gland-specific Fak deletion inhibits p53R270H-induced
breast tumour formation. Using the p53lox/lox mouse model, we
identified a contribution of FAK in loss of tumour suppressor
gene-mediated spontaneous mammary tumour formation.
However, FAK overexpression in breast cancers has been
frequently correlated with p53 mutations, a feature that is not
represented by our p53lox/lox mouse model (Golubovskaya et al,
2009). Therefore, in addition to our p53lox/lox mouse model, we
developed mice with WapCre-mediated conditional expression of
p53R270H, the mouse equivalent of human p53R273H hot spot
mutation (Wijnhoven et al, 2005), together with conditional
deletion of FAK. The conditional-floxed FAK strain was crossed
with mice conditionally expressing p53R270H and WapCre to
generate WapCre/p53R270H/þ /FAKlox/þ (referred to as FAKflox/þ )
and WapCre/p53R270H/þ /FAKflox/ mice (referred to as FAKlox/ ).
To evaluate the role of FAK in p53R270H-induced mammary
tumorigenesis, female FAKlox/þ and FAKflox/ were subjected to
one pregnancy to mediate the WapCre-mediated expression of
p53R270H point mutation and ablation FAK. Subsequently, the mice
were monitored for mammary tumour development by physical
palpation for a total time period of 70 weeks. The first onset of
mammary tumours was already at 38 weeks for FAKflox/þ and 39
weeks for FAKflox/ after p53R270H induction (Figure 3A and
Table 2) and overall survival was similar (data not shown).
Although the onset of mammary tumours was comparable, only
few mammary tumours developed in FAKflox/ mice, all of which
were observed within 50 weeks. The number of mammary tumour-
bearing mice was significantly higher in FAKflox/þ mice, indicating
that mice that still express FAK are more susceptible to mammary
tumour development than FAKlox/ mice even later in time. Sixty-
nine percent (9 out of 13 mice) of FAKflox/þ mice were tumour
bearing, all bearing one or more mammary gland tumours, with a
mean latency of 51±8.3 weeks (Figure 3A and Table 2).
In contrast, only 20 percent (4 of a total of 20 mice) of FAKflox/
mice developed mammary tumours, with a mean latency of
48±8.3 weeks, representing a clear difference in tumour formation
(unpaired t-test Po0.05, Figure 3A). Most mammary gland
tumours developed in the 4th or 5th mammary gland, 67% in
FAKflox/þ and 50% in FAKflox/ mice. Focal adhesion kinase
recombination efficiency was determined by PCR and confirmed
that FAK ablation was evident in FAKlox/þ and FAKlox/
mammary tumours (Figure 3B).
On the basis of their histological analysis, mammary tumours
that developed in FAKlox/þ and FAKlox/ animals were mostly
adenocarcinomas and solid carcinomas (Figure 3C and Table 2).
Strikingly, none of the p53R270H-driven FAKlox/þ and FAKlox/
mammary tumours were classified as carcinosarcomas. P53R270H
expression in FAKlox/þ and FAKlox/ mammary tumours was
assessed by immunohistochemical staining with CM5 and showed
accumulation of p53 in nuclei of mammary tumour cells
(Figure 4A). Accumulation of p53 was also observed in neoplastic
and hyperplastic lesions of contralateral non-tumour-bearing
glands (Figure 4A).We confirmed FAK protein level was reduced
in FAKflox/ mammary tumours by performing immunohisto-
chemistry and western blot analysis (Figure 4B–D). Focal adhesion
kinase staining on paraffin sections of the isolated tumours showed
a manifest reduction in FAK protein levels in FAKflox/ tumours
(Figure 4B), indicating that in our model FAK is successfully
deleted. However, in line with the observations made in p53lox/lox
mouse model, we obtained several mammary tumours that lack
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Figure 3. FAK expression is crucial for p53R270H-induced mammary
tumour progression. Female p53R270H/FAKflox/ and p53R270H/FAKflox/þ
mice were subjected to one pregnancy to activate WapCre resulting in
the expression of p53R270H point mutation and deletion of the floxed
Fak allele. Mice were followed for the development of mammary
tumours for a total time period of 70 weeks. (A) Mammary tumour-free
survival curves of p53R270H/FAKflox/ /WapCre (n¼20) and p53R270H/
FAKflox/þ /WapCre mice (n¼13). Time is depicted in weeks after
p53R270H expression, set at time of birth of litters (Log-rank ns,
unpaired t-test Po0.05). (B) FAK recombination PCR was used to
determine recombination of the FAK allele flanked by loxP sites. FAK
wt is 1.4 kb, FAK lox is 1.6 kb and FAK recombined is 327bp.
(C) Mammary tumours were stained with haematoxylin/eosin (HE) to
determine tumour type.
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FAK but show similar tumour latency compared with FAKlox/þ
mammary tumours. Unfortunately, the low number of tumours
obtained from FAKflox/ mice in p53R270H model does not permit
a further robust genetic comparison.
In conclusion, our data indicate that FAK is important for
p53lox/lox and P53R270H-induced spontaneous mammary tumour
development.
Mammary-specific ablation of FAK results in a remarkable
reduction in proliferation of p53lox/lox and p53R270H cells in
neoplastic lesions. We have previously shown that FAK ablation
affects mammary gland development and inhibits the lactational
differentiation process (Van Miltenburg et al, 2009). Other studies
indicate a role for FAK in tumour-cell proliferation (Lahlou et al,
2007; Provenzano et al, 2008). Deletion of FAK did not affect the
growth rate of tumours after they appeared in either p53lox/lox or
p53R270H background: typically, after detection by palpation all
tumours reached a volume of 1 cm3 within a few days. Therefore,
to determine the role of FAK in mammary tumour development in
our models, we quantified the proliferative potential by staining for
Ki67 in mammary glands that contained neoplastic and hyper-
plastic lesions, while no tumour was detected yet. In p53lox/lox and
p53R270H mice neoplastic and hyperplastic lesions were evident
already at 40 weeks, corresponding to early phases of oncogenic
transformation. P53lox/lox/FAKflox/ mammary glands showed a
significant reduction in ki67-positive cells compared with
p53lox/lox/FAKþ /þ and p53lox/lox/FAKflox/þ mammary glands
(Figure 5A and C), while number of apoptotic cells, determined
by cleaved caspase-3, was comparable in all groups (Supplementary
Figure 3). Confirmatively, reduced proliferation was also observed
in p53R270H/þ /FAKflox/ mammary glands, albeit not significant,
which is related to the limited number of p53R270H/FAKflox/
tumours (n¼ 4), suggesting that also during mammary tumour
development FAK is important for proliferation (Figure 5B and D).
Taken together, these observations indicate that FAK is required at
early stages of tumour initiation but becomes dispensable for
expansion of established tumours.
Deletion of FAK does not influence tumour type. P53R270H mice
develop mammary tumours that, based on their histomorpho-
logical characteristics, did not resemble the mammary tumours that
arose in p53lox/lox, and mammary tumour latency was significantly
shorter in P53R270H/FAKlox/þ mice compared with p53lox/lox/
FAKlox/þ (Supplementary Figure 4A). In human breast cancers, an
inverse correlation has been observed between p53 activity and
FAK expression. As P53R270H/FAKlox/þ tumours had a shorter
latency than p53lox/lox/FAKlox/þ tumours, we determined whether
this effect could be explained by differences in the FAK protein
level. Indeed P53R270H/FAKlox/þ tumours show a significant
higher FAK protein level (Supplementary Figure 4B and C),
Table 2. Tumour spectrum in FAKflox/þ and FAKflox/ p53R270H mice
FAKflox/þ FAKflox/
Total number of mice analysed 13 20
Tumour-bearing mice 9 (69%) 9 (45%)
Mammary gland tumour 9 (69%) 4 (20%)
Carcinomaa 9 4
Lymphoma 0 1
Otherb 0 5
Mean mammary gland tumour latency (wks)c 51±8.3 48±8.3
aCarcinomas could be classified in adenocarcinoma and solid carcinomas.
bOther tumours were found in the lung, bone, and colon.
cMean latency time is depicted as the number of weeks after expression of the p53R270H
mutation.
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Figure 4. Successful p53 and Fak gene recombination in p53R270H/WapCre mice. (A) Mammary glands and tumours were stained with p53 CM5 to
validate p53 accumulation, which confirms p53R270H expression. (B) FAK staining on paraffin sections of mammary tumours. Sections were
analysed by light microscopy. (C) Western blot analysis was performed on mammary tumour lysates to determine the FAK protein level.
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indicating that mammary tumour formation is dose dependent.
This observation is in line with data showing a correlation between
FAK protein level and p53 mutations (Golubovskaya et al, 2009).
Next, we wondered whether P53R270H/FAKlox/þ mice develop
from the same mammary epithelial progenitors. WapCre is
activated predominantly in the luminal compartment (Wagner
et al, 1997). To determine whether the mammary tumours
developed from the luminal-epithelial compartment, we stained
all P53R270H-driven and p53lox/lox-induced mammary glands
and tumours for cytokeratin 8 (CK8), a luminal marker, and
cytokeratin 5 (CK5), a myoepithelial or basal marker. In
contralateral non-tumour-bearing p53lox/lox mammary glands
(Figure 5E), expansion of the CK8-positive luminal compartment
was evident. Also, with exception of one FAKþ /þ mice, all
tumours were CK8 positive (Figure 5E), indicating that the
tumours developed from the luminal compartment. Interestingly,
p53R270H/þ -expressing mammary glands show expansion of CK5-
and CK8-positive epithelial cells upon expression of p53R270H
(Figure 5F), and mammary tumours that ultimately develop in
p53R270H/þ /FAKlox/þ and p53R270H/þ /FAKlox/ animals were
predominantly CK5 positive (Figure 5F). These observations were
independent of FAK background. These data suggest that p53R270H
induces tumours with basal-like characteristics, which are strik-
ingly different from the mammary tumours developed in the
p53lox/lox mouse model, as the p53lox/lox mouse model only gave
rise to CK8-positive tumours. Cytokeratin 5 status was confirmed
by western blot analysis, again clearly indicating that mammary
tumours that developed in the p53R270H mouse model were CK5
positive (Supplementary Figure 4B). In human patients, a
significant association was found between elevated p53 levels,
indicative of p53 mutations, and basal-like breast cancer, which is
characterised by CK5 expression (Rakha et al, 2009). In addition to
the expression of cytokeratin 5, gene expression analysis on
p53R270H mammary tumours showed elevated levels of several
basal markers including Trp63, Krt17, Cryab, Ptn, Col17a1 and
Slug (snai2) (Perou et al, 2000; Liu et al, 2013) (Supplementary
Figure 5). This finding is in line with human breast cancer patient
data in which p53 missense and truncating mutations are most
frequently found in the basal-like subgroup (Cancer Genome Atlas
Network, 2012). Thus, p53 null and p53 mutants lead to distinct
types of tumours, a feature that is not controlled by FAK.
DISCUSSION
Genetic alterations in the tumour suppressor protein p53 are
frequently observed in breast cancer and are often correlated with
FAK overexpression. In this study, we determined the role of FAK in
p53lox/lox- and p53R270H-induced spontaneous mammary gland
tumour development. We show that mammary neoplasia and
hyperplasia are evident in FAK-deleted mammary glands, indicating
that FAK does not fully prohibit the initiation of these lesions.
However, these lesions contained reduced levels of proliferative
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Figure 5. Mammary-specific ablation of FAK leads to reduced proliferation in preneoplastic ductal lesions. (A, B) Mammary glands from p53lox/
lox/FAKþ /þ (n¼17), p53lox/lox/FAKflox/þ (n¼15) and p53lox/lox/FAKflox/ (n¼11) mice, and p53R270H/FAKflox/þ (n¼ 6) and p53R270H/FAKflox/
(n¼15) mice, obtained over the course of the experiment, were stained for the proliferation marker Ki67. (C, D) Percentage of P53lox/lox (Po0.01)
and p53R270H ductal structures containing Ki67þ mammary epithelial cells. Five p53R270H/FAKflox/ mammary glands were excluded as they did
contain too few ductal structures to quantify the ki67-positive cells. (E, F) Paraffin sections of p53lox/lox and p53R270H mammary tumours and non-
tumour-bearing mammary glands were stained for luminal marker cytokeratin 8 (CK8) and myoepithelial marker cytokeratin 5 (CK5). Fluorescent
staining was analysed by confocal laser scanning microscopy. Scale bar is 50mm.
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mammary epithelial cells, while no increase in apoptosis was
observed. In conjunction, this led to a significant reduction in
mammary tumour incidence in both p53-dependent mammary
tumour development models, indicating that FAK is essential for the
progression of mammary hyperplasia towards mammary tumours.
Comparison of the p53R270H and p53lox/lox mouse models
revealed that the expression of p53R270H mutant resulted in
accelerated mammary tumour development. These results indicate
that the p53R270H point mutation, apart from having a dominant-
negative affect on the wild-type p53 allele, may also acquire gain-
of-function, which facilitates acceleration of mammary tumour
development. Although a gain-of-function for p53R270H was not
found by Wijnhoven et al (2007), a recent paper describes that
p53R270H enhances the transition from intra-epithelial neoplasia to
invasive carcinoma (Heinlein et al, 2008). Interestingly, FAK
expression was elevated in p53R270H tumours compared with
p53lox/lox tumours, suggesting that the increase in FAK protein
contributes to the accelerated tumour development of p53R270H-
driven tumours.
Interestingly, based on morphology and cytokeratin markers
p53R270H and p53lox/lox mammary tumours have a different
appearance. Carcinosarcomas, as observed in p53lox/lox mouse
model, are relatively uncommon in humans, but based on their
appearance would likely be part of the metaplastic breast cancer
subtype. Metaplastic breast carcinoma (MBC) is an umbrella term
for a heterogenous group of cancers, which are characterised based
on the presence of neoplastic cells with squamous or mesenchymal
morphology, such as spindle cells. Metaplastic breast carcinomas
frequently harbour mutations in the Trp53 gene, indicating that the
p53lox/lox mouse model potentially mimics a rare human breast
cancer subtype (Weigelt et al, 2014). Although FAK depletion
inhibited the development of mammary gland tumours in both
models, FAK did not affect the differentiation status.
The MMTV-PyMT mouse model for breast cancer has been
extensively used to study the role of FAK in mammary
tumorigenesis and implicated a role for FAK in breast cancer
progression (Lahlou et al, 2007, 2012; Provenzano et al, 2008; Luo
et al, 2009; Pylayeva et al, 2009). In line with our findings,
mammary gland-specific Fak deletion was shown to reduce the
incidence of mammary tumours in the PyMT mice. The studies
from Pylayeva et al (2009) revealed that the FAK-deficient PyMT-
transformed cells displayed diminished invasive and metastatic
capacity. In addition, these cells displayed both growth arrest and
apoptosis. After detection by palpation both p53R270H and the
p53lox/lox tumours grew within a few days to a size that requires
sacrifice of the animals. In these animals, we were unable to detect
clear metastatic lesions at the macroscopic level, although we can
not exclude that small microscopic lesions were present at distant
sites. In addition, it was shown previously that FAK deficiency has
a severe impact on mammary cancer stem/progenitor cells.
Focal adhesion kinase deletion reduced the pool of cancer stem/
progenitors, decreased their self renewal and migration in vitro,
and comprised their tumorigenicity and maintenance in vivo (Luo
et al, 2009). The reduction in incidence of mammary tumours we
observed in our mouse models could be due to decreased numbers
of mammary cancer stem/progenitor cells. This fits with the
reduced proliferation capacity in preneoplastic lesions in FAK-null
mammary glands. Yet, future studies should clarify a role for FAK
in the regulation of the survival and/or proliferation of (tumour
initiation) stem/progenitor cells. Regardless, the reduced prolif-
erative capacity of preneoplastic cells in the FAK-deleted
mammary glands would reduce the change for additional pro-
oncogenic DNA lesions. The differential loss of such a population,
which is most likely a dynamic event and progresses over time,
may partly explain the bi-phasic effect of the consequences of FAK
deletion on mammary gland tumour development. Remarkably, in
dept analysis showed that the few tumours that did develop in
FAKflox/ mice were both genetically and phenotypically compar-
able to FAKflox/þ tumours. Possibly, at the time of mammary
tumour initiation and early mammary tumour development, FAK
may not be efficiently deleted yet. Future next generation exon-
sequencing studies of both preneoplastic and neoplastic material
could unveil the underlying genetic events and possible escape
mechanisms of the suppression of tumour progression in the
absence of FAK.
Our data indicate a functional relationship between p53 and
FAK in mammary tumour development. Since p53 regulates FAK
expression (Golubovskaya et al, 2008), it would therefore be
relevant to correlate the protein levels for FAK in human breast
cancer patients expressing the p53R273H mutation (the human
equivalent of mouse R270H). In addition, mRNA expression
analysis on tumour samples from p53R270H and p53lox/lox tumours
could provide more insight into pathways that are differentially
regulated in these tumours. These data might shed light on
additional functions of the p53R270H mutation. As most human
breast cancers express mutant p53 and most tumours express
elevated levels of FAK, these patients might respond well to FAK
inhibitors, ultimately resulting in reduction of tumour size and/or
aggressiveness.
In conclusion, we demonstrate that FAK is important in the
spontaneous development of mammary tumours in p53lox/lox and
p53R270H mouse models through inhibition of cell proliferation.
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